Engflag
Advertisements

Glimestar M1

Quick links to important sections

Glimestar M1

Glimestar M1_EN
Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Glimestar M1

Property Description
Active Ingredients Glimepiride and Metformin Hydrochloride
Form Oral Tablet (solid oral formulation)
Pharmacological Class Antidiabetic Agent (Oral Hypoglycemic Agent)
Common Use Management of Type 2 Diabetes Mellitus
Origin Synthetic

What Type of Medicine is Glimestar M1?

Glimestar M1 is a prescription-only, synthetic antidiabetic agent classified specifically as an Oral Hypoglycemic Agent (OHA), formulated for the comprehensive management of Type 2 Diabetes Mellitus. It is presented as a solid oral tablet and is consistently categorized as a Fixed-Dose Combination (FDC) product, meaning it delivers two separate therapeutic agents in a single preparation. This combination is recognized for its role in the treatment of diabetes, underscoring its established place in therapy. This FDC approach is a clinically recognized strategy intended to simplify the drug regimen compared to taking the two components separately.

Composition: Glimepiride, Metformin, and Dual Action

Glimestar M1 contains two primary active ingredients: Glimepiride and Metformin Hydrochloride, which together provide a dual therapeutic approach to hyperglycemia. Glimepiride belongs to the sulfonylurea class, and its mechanism involves acting as an insulin secretagogue. Concurrently, Metformin Hydrochloride belongs to the biguanide class, functioning primarily as an insulin sensitizer. This combination, uniting agents from both classes, provides a rational and effective means of improving blood sugar control in patients with Type 2 Diabetes. The combination of these mechanisms helps address two major metabolic issues at once. The Glimestar M1 brand specifically provides an oral formulation for adults, distinguishing it from non-oral or pediatric-focused antidiabetic products.

The General Purpose of Glimestar M1 for Glycemic Control

The general purpose of the Glimestar M1 combination is to achieve effective and sustained lowering of blood sugar and improve overall glycemic control in adult patients with Type 2 Diabetes. The medicine addresses the core metabolic abnormalities associated with the condition, which include both reduced insulin secretion and increased insulin resistance in peripheral tissues. By addressing these two key defects concurrently, the synergistic effect of the dual components supports continuous management of hyperglycemia, a typical use scenario when diet and exercise alone have proven insufficient. The long-term efficacy of this dual-action strategy is a recognized approach for maintaining metabolic stability.

Advertisements

What side effects are possible with Glimestar M1?

Possible Side Effects and Safety Information

The safety profile for Glimestar M1, a combination of Glimepiride and Metformin, is officially documented by regulatory authorities (such as the FDA and EMA) and is defined by the known risks of its two active components.

Serious Adverse Reactions

The medicine is associated with two primary serious, though infrequent, risks:

  • Lactic Acidosis: This is a very rare, but serious and potentially fatal, metabolic complication primarily linked to the Metformin component. The risk increases significantly in the presence of severe renal impairment or excessive alcohol intake.
  • Severe Hypoglycemia (Low Blood Sugar): This is the primary risk associated with the Glimepiride component. Severe cases can lead to loss of consciousness, coma, or permanent damage.

Common Adverse Reactions

Side effects categorized as Common in regulatory documents often include gastrointestinal disturbances and headache.

System-Organ Class Common Adverse Effects
Gastrointestinal Diarrhea, Nausea, Vomiting, Abdominal pain, Metallic taste
Nervous System Headache, Dizziness

Safety Considerations and Restrictions

Official labeling defines specific restrictions for use to mitigate serious risk:

  • Contraindications: The medicine is formally contraindicated in patients with severe renal impairment (kidney function issues), severe hepatic impairment (liver function issues), and acute or chronic metabolic acidosis. It is generally not recommended during pregnancy or lactation.
  • Situational Discontinuation: The Metformin component must be temporarily discontinued before certain medical procedures, such as radiological studies involving iodinated contrast agents, to reduce the risk of Lactic Acidosis. The risk of gastrointestinal side effects is typically higher at treatment initiation. Long-term use is associated with a decrease in Vitamin B12 serum levels.
Advertisements

Overdose and Emergency Response

The official regulatory profile for an overdose of this combination medication addresses the severe risks posed by both active components, Glimepiride and Metformin.

Overdose Presentations and Manifestations

Overdose may lead to two distinct, life-threatening conditions: Severe Hypoglycemia (from Glimepiride) and Lactic Acidosis (from Metformin). Severe Hypoglycemia symptoms documented in regulatory labeling include confusion, coma, seizures, tachycardia, sweating, and tremor. Lactic Acidosis may present with non-specific signs such as malaise, myalgia, abdominal pain, and acidotic dyspnea, and is confirmed by laboratory findings of elevated blood lactate levels (>5 mmol/L) and anion gap acidosis.

Immediate Actions and Urgent Help

Immediate medical attention or emergency services must be contacted upon any suspicion of overdose or the onset of severe symptoms. The regulatory standard classifies both severe hypoglycemia and lactic acidosis as medical emergencies that require immediate hospitalization.

  • Supportive Procedures: For Metformin accumulation, prompt hemodialysis is the officially documented measure for drug removal. For Glimepiride overdose, glucose or dextrose administration is the necessary intervention, and patients require hospital observation for 24 to 48 hours due to the risk of recurring hypoglycemia.
  • Population Note: There is an increased risk and severity of Lactic Acidosis specifically documented in patients with renal impairment.
Advertisements

Therapeutic Uses of Glimestar M1

Quick Facts

  • Therapeutic Domain: Management of Type 2 Diabetes Mellitus in adults.
  • Primary Benefit: Supports the lowering of high blood glucose (sugar) levels.
  • Usage Context: Used when diet and physical activity alone are insufficient for blood sugar control.
  • Long-term Goal: Helps to manage the risk of serious complications associated with diabetes.

Glimestar M1 is a prescription medication used to assist in the management of Type 2 Diabetes Mellitus in adult patients. The medication is an approved component of a comprehensive diabetes care plan, which includes following a balanced diet and maintaining regular physical activity.

Its primary therapeutic role is to support the regulation of blood sugar levels. By helping to manage high blood glucose, Glimestar M1 contributes to the maintenance of overall glycemic control. This intervention is designed for patients whose blood sugar levels are not adequately controlled by lifestyle changes or monotherapy with a single anti-diabetic agent.

Consistent use, as prescribed by a healthcare provider, can help reduce the potential for serious long-term health concerns associated with uncontrolled Type 2 diabetes, such as issues affecting the kidneys, eyes, and nerves. The goal of treatment is to support patients in achieving and maintaining targeted blood sugar stability.

Regulatory References

  1. NIH StatPearls guidance
Advertisements

Eligibility and Restrictions for Use

The eligibility profile for this fixed-dose combination is strictly defined by official regulatory documentation. The medicine is approved for use in adults with Type 2 Diabetes Mellitus when blood sugar levels are not adequately controlled by lifestyle changes or by monotherapy with either glimepiride or metformin.

Contraindications and Absolute Restrictions

Use is contraindicated (must not be used) in individuals with Type 1 Diabetes Mellitus, Diabetic Ketoacidosis, or any other form of acute or chronic metabolic acidosis. It is strictly prohibited in patients with severe renal failure (Glomerular Filtration Rate (GFR) less than 30 mL/ min) and severe hepatic function disorders. Other contraindications include hypersensitivity to the active components or related sulfonylureas, and conditions leading to tissue hypoxia (e.g., severe heart failure). The medicine is also contraindicated during pregnancy and for breast-feeding women.

Population Limitations

The medicine is not recommended for use in children and adolescents (under 18 years) as safety and efficacy have not been established. Use in older adults requires caution and regular assessment of renal function. In cases of moderate renal impairment (GFR 30 –59 mL/ min), use is restricted and requires careful dose adjustment and monitoring.

Advertisements

What should I know about interactions with other medicines?

Glimestar M1 Interactions with other medicines and products

Official regulatory information regarding Glimestar M1 interactions is structured around the two active components, Glimepiride and Metformin.

Classification Interacting Agents Regulatory Constraint
Procedural Restriction Iodinated Contrast Media The Metformin component must be temporarily discontinued at the time of or prior to the imaging procedure and restarted only after 48 hours with verified stable renal function [FDA 5.4].
Clearance Reduction Cimetidine, Ranolazine, Vandetanib, Dolutegravir These cationic drugs officially reduce Metformin clearance by inhibiting renal transporters (OCT/MATE), leading to increased systemic exposure [FDA 1.3].
Absorption Timing Colesevelam Glimepiride must be administered at least 4 hours prior to Colesevelam to prevent documented reduced absorption and loss of exposure [FDA 2.4].
Metabolic Disruption CYP2C9 Inhibitors (e.g., Fluconazole) Documented to increase Glimepiride plasma concentration by inhibiting the CYP2C9 enzyme pathway [SmPC 2.2].
Pharmacodynamic Effect Insulin, ACE Inhibitors, Glucocorticoids, Diuretics Certain drug classes are listed as either potentiating (e.g., Insulin, ACE Inhibitors) or reducing (e.g., Glucocorticoids, Thiazide Diuretics) the blood-glucose-lowering effect [SmPC 2.3].

Excessive alcohol intake is specifically documented to potentiate Metformin’s effect on lactate metabolism, significantly increasing the risk of lactic acidosis [FDA 1.4]. Co-administration with drugs that acutely impair renal function (e.g., NSAIDs) also increases the risk of Metformin accumulation [SmPC 3.2]. These statements are based solely on information found in government-approved prescribing documents.

Advertisements

Mechanism of Action

The action of Glimestar M1 is based on two components that engage complementary mechanistic domains to influence systemic glucose dynamics.

Stimulating Pancreatic Insulin Release

Glimepiride acts by inhibiting the K ATP ion channel on pancreatic beta-cells, triggering a molecular cascade that results in the exocytosis of stored insulin. This mechanism leads to an increased systemic concentration of insulin.

Suppressing Liver Glucose Production

This action, driven by Metformin, involves the inhibition of mitochondrial complex 1 in hepatocytes. This ultimately activates the AMPK energy-sensing pathway, which suppresses the gene expression of enzymes required for Hepatic Glucose Production ( HGP). The resulting physiological effect is a direct decrease in the rate of glucose entry from the liver into the circulation.

Enhancing Peripheral Tissue Sensitivity

Metformin also functions by activating AMPK in peripheral tissues like skeletal muscle. This action promotes the movement of GLUT4 glucose transporters to the cell surface, which enhances the clearance of glucose from the extracellular space. This mechanistic domain improves the tissues' response to circulating insulin, thereby increasing the rate of glucose utilization.

Advertisements

Dosage and Administration Information

How to Use Glimestar M1

This section outlines the general principles for the administration of the fixed-dose combination Glimestar M1 (Glimepiride and Metformin Hydrochloride).

Administration and Dosage Principles

Instruction Principle of Use
Route of Administration Glimestar M1 is intended solely for oral administration as a tablet.
Dosing Frequency The medicine is typically taken once daily (OD).
Timing and Intake The dose must be administered with the first main meal of the day or immediately before a substantial meal, and the tablets must be swallowed whole.
Initiation and Adjustment Treatment begins with a low starting dose, and any dosage adjustment (titration) should be performed gradually—not more frequently than every 1 to 2 weeks—based on clinical response.
Maximum Dose The maximum daily dose for the Glimepiride component is generally 8 mg, while the Metformin component is limited to 2000 mg.

Special Conditions for Administration

Administration requires consideration of specific physiological and procedural conditions. The dose must be reduced or discontinued based on the patient's estimated Glomerular Filtration Rate (eGFR), as kidney function directly constrains the safe use of the Metformin component. Furthermore, the medication must be temporarily stopped before or at the time of certain surgical procedures or radiologic studies involving the use of iodinated contrast materials. If a dose is missed, a patient should not take a double dose to compensate.

Advertisements

Recent Clinical Evidence

Glimestar M1: Recent Clinical Evidence

Evidence for Use in Type 2 Diabetes Management

The evidence base for the glimepiride and metformin combination primarily relies on randomized controlled trials (RCTs), which were used to compare different treatment approaches, alongside observational studies that track how the medicine is used in real-world settings. Research examined the use of this fixed-dose combination (FDC) in adults with Type 2 Diabetes Mellitus (T2DM). The main focus of these trials was monitored changes in key blood sugar markers.

Studies explored outcomes by measuring shifts in Glycated Hemoglobin (HbA1c), which reflects long-term blood sugar control, and Fasting Plasma Glucose (FPG) levels. These trials used the achievement of specific glycemic targets as a primary study endpoint. Findings describe patterns observed in the studies related to changes measured in these biomarker levels. Furthermore, studies monitored the equivalence of outcomes when the two active components were taken as a single fixed tablet versus when they were taken as separate tablets, and research describes that these approaches were observed to have comparable outcomes in the study period.

Comparative Clinical Trials and Combination Studies

Comparative research was conducted in patients whose blood sugar levels were not adequately managed by using only one anti-diabetic medicine (monotherapy). Studies were designed to compare the combination against an increased dose of the single medicine the patient was already taking (uptitration).

Trials reported measurements of HbA1c and FPG when comparing the FDC against uptitration of metformin alone. Research describes changes measured during the study period, indicating that the combination was evaluated in populations with certain levels of blood sugar. Findings indicate patterns related to differences in outcomes between the two treatment approaches, which helps contextualize how the combination fits within the broader evidence landscape.

Evidence in Specific Patient Populations and Comorbidities

The majority of studies monitored adults with T2DM, particularly those with a history of inadequate control while using a single agent.

Studies focused on populations including those with common comorbidities like hypertension or elevated cholesterol (dyslipidemia). Research monitored how outcomes related to measured biomarkers were observed in patients who also had conditions like hypertension or elevated cholesterol (dyslipidemia). Evidence provides insight into short-term changes for these groups, contributing to the broader evidence landscape. The results apply only to the populations studied.

Long-Term Evidence and Durability of Effect

The research landscape includes trials observing responses over defined time intervals. However, the follow-up durations were limited for many randomized controlled trials focusing specifically on the fixed-dose combination, often lasting 16 to 24 weeks.

Long-term effects are not fully established based on these shorter studies. Therefore, data for long-term outcomes, such as the medication's impact on cardiovascular or microvascular complications of diabetes, are primarily derived from studies on the individual component drug classes themselves, rather than the specific fixed tablet. Research provides context.

Areas of Scientific Uncertainty and Research Gaps

Despite the existing body of evidence, certain areas of scientific uncertainty remain, and research is ongoing.

  • Trial Duration: The evidence is limited for long-term outcomes, as the follow-up durations of FDC-specific studies were typically short-term. There is limited information for long-term outcomes.
  • Comparative Outcomes: Studies monitored differences in the incidence of certain events when comparing this combination to other anti-diabetic options. Findings describe patterns related to monitored outcomes like hypoglycemia and shifts in body weight, which were observed in some comparative studies.
  • Subgroup Data: Data for certain groups remain insufficient, meaning the evidence quality varies across studies, and subgroup findings are uncertain for some populations.

Key Studies & References

  1. Comparison of the Efficacy and Safety of Glimepiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial
  2. Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients (NCT01459809)
  3. Effectiveness of Glimepiride and Metformin Fixed- dose Combination Therapy in Patients with Type 2 Diabetes and Comorbidities
  4. Initial Combination Therapy in Type 2 Diabetes (Context for long-term class effects and guidelines)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Glimestar M1 (FAQ)

Q: Is Glimestar M1 different from taking Metformin alone?

A: Yes, Glimestar M1 is a fixed-dose combination containing two active ingredients: Glimepiride and Metformin. Official regulatory indications state that this combination is used for adults with Type 2 Diabetes whose blood sugar is not adequately managed by taking either of the single components alone. The two components are described as acting through different, complementary methods to influence systemic glucose dynamics.

Q: Does Glimestar M1 work immediately after I start taking it?

A: The Glimepiride component of the medicine begins to have a blood-sugar-lowering effect relatively quickly after administration, with the maximum single-dose effect typically seen within a few hours. However, the full impact on long-term blood sugar markers, such as HbA1c (Glycated Hemoglobin), is generally evaluated over several weeks of continuous use, as described in clinical information.

Q: How long does it usually take to see an effect from Glimestar M1?

A: Clinical studies supporting the use of the combination often evaluate long-term blood sugar control by measuring changes in the marker HbA1c over defined study periods. Patterns related to significant changes in this long-term marker are typically observed after several weeks of continuous therapy, based on research findings.

Q: Is it normal to have mild stomach upset when starting Glimestar M1?

A: Regulatory documents list gastrointestinal disturbances, such as diarrhea, nausea, vomiting, and abdominal pain, as common adverse effects. Official product information notes that the risk of experiencing these effects is typically higher when treatment is first initiated.

Q: Are there any common long-term side effects noted for Glimestar M1?

A: Long-term use of the Metformin component is officially associated with a decrease in Vitamin B12 serum levels. While very rare, lactic acidosis is noted as the most serious long-term risk associated with the Metformin component.

Q: Do people typically experience weight gain with Glimestar M1?

A: Weight gain is officially noted as an adverse reaction associated with the Glimepiride component of the drug. The other component, Metformin, is not typically associated with weight gain. Clinical studies monitor for shifts in body weight.

Q: Does Glimestar M1 interact with common cold or flu medicines?

A: Official drug documents list interactions with specific drug classes that are sometimes found in common cold or flu remedies. For instance, drugs like Glucocorticoids and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) can affect blood sugar control or increase the accumulation of Metformin in the body. This potential interaction is noted by regulators as requiring monitoring.

Q: What should be avoided while using Glimestar M1, besides other drugs?

A: Official documents explicitly warn against excessive alcohol intake because it significantly increases the risk of lactic acidosis. Additionally, the Metformin component is required to be temporarily discontinued before or during certain medical procedures, such as radiological studies involving iodinated contrast agents.

Q: Can Glimestar M1 change my appetite?

A: The most common adverse effects are gastrointestinal, including nausea and vomiting. Loss of appetite is officially listed as a symptom associated with the serious complication of lactic acidosis.

Q: What kind of studies support the use of Glimestar M1?

A: The evidence base primarily relies on randomized controlled trials (RCTs) and observational studies in adults with Type 2 Diabetes. These studies evaluate the medicine's effects by monitoring changes in blood sugar markers like HbA1c and Fasting Plasma Glucose (FPG).

Q: Is Glimestar M1 a common treatment choice for newly diagnosed patients?

A: The official indication states the medicine is for use when blood sugar levels are not adequately controlled by lifestyle changes (diet and exercise) or by monotherapy with either glimepiride or metformin alone. It is indicated for use when initial treatment steps have not adequately controlled blood sugar levels, according to regulatory information.

Q: Why do some people need a combination pill like Glimestar M1?

A: The combination is indicated for use when a patient’s blood sugar is not adequately managed by using only one anti-diabetic medicine (monotherapy). The two components provide a dual therapeutic approach, uniting agents that stimulate insulin release and those that improve the body’s response to insulin.

Q: Is Glimestar M1 used for conditions other than diabetes?

A: No, official drug labeling explicitly indicates this medicine as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus. It is officially contraindicated for use in Type 1 Diabetes Mellitus or Diabetic Ketoacidosis.

Q: Is it safe to drive or operate machinery while taking Glimestar M1?

A: Hypoglycemia (low blood sugar) is a known serious risk of this medicine. Regulatory documents warn that the ability to concentrate and react may be impaired as a result of hypoglycemia. Impairment is noted as a potential risk factor in situations like driving or operating machinery.

Q: Can Glimestar M1 cause changes in vision?

A: Temporary visual impairment, such as blurred vision, can occur as a symptom of low blood sugar (hypoglycemia), which is a risk with the Glimepiride component. This visual change is temporary and related to shifts in blood glucose levels.

Q: What lifestyle changes are usually recommended while on Glimestar M1?

A: The medicine is officially indicated for use as an adjunct to diet and exercise to improve blood sugar control. Regulatory guidance specifies that Glimestar M1 is considered a treatment in addition to a proper dietary regimen and regular physical activity.

Q: Are there certain foods that interact negatively with Glimestar M1?

A: Regulatory guidance on drug interactions focuses primarily on excessive alcohol intake and specific medicines. The instructions for use state the medicine must be taken with the first main meal of the day or immediately before a substantial meal, as it is intended to be used alongside a proper dietary regimen.

Q: Can taking Glimestar M1 lead to a B12 deficiency?

A: Official safety documents indicate that long-term use of the Metformin component is associated with a decrease in Vitamin B12 serum levels. Regulatory information states that this condition may be subject to monitoring and potential supplementation.

Q: How is Glimestar M1 designed to release its ingredients in the body?

A: Glimestar M1 is supplied as a solid oral tablet that delivers its two active agents in a single preparation. While this product is an immediate-release tablet, official dosage forms for medicines containing Metformin may also include an extended-release (ER) or prolonged-release (PR) design.

Q: Do other medications commonly used for diabetes interact with Glimestar M1?

A: Yes, official documents list that the combination can interact with Insulin, where Insulin can potentiate the blood-glucose-lowering effect. Regulatory documents note the potential need for caution when co-administering with other anti-diabetic medications due to the potential risk of hypoglycemia.

Q: Why might a doctor switch a patient from one diabetes drug to Glimestar M1?

A: The medicine is indicated for use when a patient's blood sugar levels are not adequately controlled by using either of the single components alone (Metformin or Glimepiride). This combination strategy is officially supported by clinical studies that evaluate its use in patients whose condition was inadequately managed by monotherapy.

Q: Can Glimestar M1 make me feel lightheaded or dizzy?

A: Dizziness is officially listed as a common adverse effect in safety documents. Furthermore, dizziness and lightheadedness are documented symptoms of hypoglycemia (low blood sugar), which is a serious risk of the Glimepiride component.

Advertisements

How should Glimestar M1 be stored and disposed of?

How to Store and Dispose of Glimestar M1?

Storage and disposal requirements for Glimestar M1 tablets are strictly defined by regulatory labeling to maintain stability and prevent accidental harm.

Storage Conditions

  • The tablets must be stored at Controlled Room Temperature, which requires keeping the product below 30 C and protecting it from freezing.
  • Store the medicine in the original container or blister pack it came in and keep it tightly closed to protect it from excess heat and moisture.
  • The labeled shelf life is 3 years while stored under these conditions.

Disposal and Safety

  • As a safety measure, Glimestar M1 must be kept out of the reach and sight of children.
  • Disposal of expired or unused medicine must follow official guidance: ask a healthcare professional or pharmacist how to properly discard the tablets according to local pharmaceutical waste handling rules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Glimestar M1 found in:

A-Z Index: